(A and B) The fat masses of male (A) and female (B) mice at 28 weeks of age on different diets.
(C and D) The serum leptin of male (C) and female (D) mice at 30 weeks of age on different diets.
(E and F) The lean masses of male (A) and female (B) mice at 28 weeks of age on different diets. * indicates significant (p<0.05) increase compared to wild-type mice under the same food condition. The numbers of mice are 8–14 mice per group. Data are expressed as means ± SEM.

(A) Blood glucose levels of orexin-related gene mutant mice on different fat diets.
(B) Serum insulin levels of orexin-related gene mutant mice on different fat diets.
(C) Glucose tolerance test showed that the blood glucose levels of CAG/orexin mice were significantly lower than those of wild-type littermate mice on a high fat diet after the administration of glucose.
(D) Glucose tolerance test showed that the blood glucose levels of OX1R^−/−; CAG/orexin mice were significantly lower than those of OX1R^−/− mice on a high fat diet after the administration of glucose. Data are expressed as means ± SEM.
(E) Glucose tolerance test showed that there is no significant difference in the blood glucose levels between OX2R^−/−; CAG/orexin mice and OX2R^−/− mice on a high fat diet after the administration of glucose (p=0.33).
The numbers of mice are 8–14 mice and 6–10 mice per group for blood glucose and insulin measurement, and glucose tolerance test, respectively. Data are expressed as means ± SEM. *p<0.05

(A) The body weight growth of ob/ob; CAG/orexin male mice was similar to that of ob/ob male mice (p=0.76).
(B) Fat mass of 28 week-old ob/ob male mice with or without CAG/orexin transgene. There is no significant difference in fat mass for both male and female. 13–20 mice per group.
(C) The body weight growth of OX2R agonist-infused ob/ob mice was similar to that of vehicle-injected ob/ob mice maintained on a low fat (C) and a high fat diet. Data are expressed as means ± SEM.

(A, B) Body weight curves of wild-type male (A) and female (B) mice on a high fat diet were significantly higher than those of wild-type mice on a low fat diet (p<0.0005, both sexes). CAG/orexin mice did not differ significantly under low fat and high fat dietary conditions (p= 0.51 male; p=0.13 female).
(C, D) Body weight curves of OX1R^−/− male (C) and female (D) mice on a high fat diet were significantly higher than those of OX1R^−/− mice on a low fat diet (p<0.0001 in male; p<0.01 in female). OX1R^−/−; CAG/orexin male mice did not differ significantly between low fat and high fat dietary conditions (p=0.21). The body weights of OX1R^−/−; CAG/orexin female mice on a high fat diet were significantly less than those of OX1R^−/− mice on a high fat diet (p<0.01), in spite of no body weight difference between OX1R^−/−; CAG/orexin female mice and OX1R^−/− female mice on a low fat diet (p=0.50).
(E,F) The body weight growths of OX2R^−/− male (E) and female (F) mice on a high fat diet were significantly higher than those of OX2R^−/− mice on a low fat diet (p<0.0001 in male; p<0.005 in female). Likewise, OX2R^−/−; CAG/orexin male (E) and female (F) mice showed significant weight gain on a high fat diet compared to those on a low fat diet (p<0.0005 in male; p<0.001).
Body weights of mice measured weekly from the age of 3 weeks to 30 weeks. A high fat diet started at the age of 8 weeks (dotted line). The numbers of mice are 10–14 mice per group. * indicates significant difference between different diet condition for each genotypic group according to post-hoc analysis at each time point. Significant difference in (F) for OX2R^−/− mice and OX2R^−/−; CAG/orexin are indicated by one asterisk. Data are expressed as means ± SEM.

(A, B) The energy expenditure with effective mass correction (A) and respiratory quotient (B) sampled every 40 min over 24 hr of CAG/orexin mice and wild-type mice at 16–20 weeks of age.
(C, D) The energy expenditure with effective mass correction (A) and respiratory quotient (B) over 24 hr of OX1R^−/−; CAG/orexin mice and OX1R^−/− mice.
(E, F) The energy expenditure with effective mass correction (A) and respiratory quotient (B) over 24 hr of OX2R^−/−; CAG/orexin mice and OX2R^−/− mice.
(G, H) The averaged energy expenditure with effective mass correction (G) and respiratory quotient (H).
(I) Averaged daily high fat diet intake of CAG/orexin mice and wild-type mice for 14 days.
The numbers of mice are 6–9 mice per group. Data are expressed as means ± SEM.

(A) The daily body weight changes of chronically ICV injected mice. ICV and high fat diet begin at day 0. The body weight growths of the OX2R selective agonist-injected mice (0.5 nmol/d) are significantly lower than those of vehicle-injected mice on a high fat diet (p<0.0005), whereas there is no significant difference in the body weight growth between them on a low fat diet (p=0.45).
(B) The fat masses change of mice administered with the OX2R-selective agonist or vehicle on different fat diets during 14 days.
(C) The oxygen consumption with effective mass correction of OX2R agonist-infused mice on a high fat diet were higher than vehicle-infused mice (p<0.0005, repeated ANOVA). Data were sampled every 30 min.
(D) The respiratory quotient of OX2R agonist-infused mice on a high fat diet was similar to that of vehicle-infused mice.
(E) The averaged daily food intake of mice injected with the OX2R selective agonist or vehicle on different fat diets during 14 days.
(F) Hypothalamic gene expressions at the end of OX2R selective agonist administration are determined using q-PCR. Gene expressions are normalized by GAPDH.
(G) Immunostaining for c-Fos in ARH region of mouse on a high fat diet during central administration of OX2R agonist or vehicle; 3V, third ventricle.
(H) The number of c-Fos positive cells in ARH region.
The numbers of mice per group are 7–14 mice, 6–7 mice, and 5–6 mice for (A, B, C), (D, G, H), and (E,F), respectively. Data are expressed as means ± SEM.

(A) The body weight changes during chronic ICV injection of leptin (2ug/day) for 14 days, CAG/orexin mice on a low fat diet show larger weight loss compared with wild-type mice (p<0.05).
(B) Daily food intake of CAG/orexin mice during chronic injection of leptin is smaller than that of wild-type mice.
(C) Hypothalamic gene expressions at the end of leptin administration. 6–8 mice per group. Data are expressed as means ± SEM. *p<0.05